The most recent news and industry headlines are presented in this section. Our dedicated team closely observes the pharmaceutical industry and keeps you informed of the most recent developments around the Europe.
RELIEF THERAPEUTICS Holding SA SWXRLF has recently entered into an exclusive licensing agreement with Acer Therapeutics Inc for the development and commercialization of OLPRUVA sodium phenylbutyrate
Laurent Pharmaceuticals Inc headquartered in Montreal has received approval from Health Canada to initiate the ESSOR trial a Phase randomized placebocontrolled study
Roche SIX RO ROG OTCQX RHHBY has received approval from the European Commission to expand the use of Evrysdi risdiplam within the European Union EU
Cantex Pharmaceuticals a clinicalstage pharmaceutical company focused on developing innovative therapies for cancer and lifethreatening conditions has announced the initiation of a Phase clinical trial
Sandoz a major player in the field of generic and biosimilar medicines has successfully concluded the acquisition of the global brand rights for Mycamine micafungin sodium a leading systemic antifungal agent This acquisition was made from Astellas
Ceapro Inc publicly traded as CZO on TSXV and as CRPOF on OTCQX a burgeoning biotechnology enterprise specializing in the development and commercialization of active ingredients for the healthcare and cosmetic sectors has announced a significant amen...
MapLight Therapeutics a clinicalstage biopharmaceutical company has successfully completed a second Phase clinical trial for its novel compound ML This compound is designed to target MM muscarinic receptor agonists with the aim of addressing brain
Alentis Therapeutics a clinicalstage biotechnology company has been granted Fast Track development status by the US Food and Drug Administration FDA for their drug candidate ALEC This drug is being developed to treat patients with recurrent or metast...
Paradigm Therapeutics Inc a prominent biopharmaceutical firm has successfully concluded the acquisition of the global rights to SD from Amicus Therapeutics SD represents a topical remedy designed to address all subtypes of Epidermolysis Bullosa EB
Ventus Therapeutics has commenced a Phase clinical trial for VENT a groundbreaking oral NLRP inhibitor engineered to address neuroinflammatory diseases Marcelo Bigal MD PhD the CEO of the company expressed enthusiasm about reaching this pivotal junc...
